Maintenance chemotherapy for ovarian cancer

Abstract

There is no evidence to suggest that the use of platinum agents or doxorubicin used as maintenance chemotherapy is more effective than observation alone. Further investigations regarding the effect of paclitaxel used as maintenance chemotherapy are required.

Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers

“…[ 74–78 ] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [ 61,79–81 ]…”

“…[74][75][76][77][78] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [61,[79][80][81] The course of the illness determines the feasibility of secondary cytoreduction surgery in these advanced cases, as well as the surgical strategy of choice, including open, laparoscopic, or robotic approaches. Pathological variables such as extrapelvic involvement, carcinomatosis, and extent of disease progression determine complete cytoreduction.…”

Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers

“…[ 74–78 ] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [ 61,79–81 ]…”

“…[74][75][76][77][78] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [61,[79][80][81] The course of the illness determines the feasibility of secondary cytoreduction surgery in these advanced cases, as well as the surgical strategy of choice, including open, laparoscopic, or robotic approaches. Pathological variables such as extrapelvic involvement, carcinomatosis, and extent of disease progression determine complete cytoreduction.…”

Impact of Environmentally Relevant Concentrations of Bisphenol A (BPA) on the Gene Expression Profile in an In Vitro Model of the Normal Human Ovary

“…The results show that BPA exposure has a considerable impact on 10 genes: ANAPC2, AURKA, CDK1, CCNA2, CCNB1, PLK1, BUB1, KIF22, PDE3B, and CCNB3, which are also associated with progesterone-mediated oocyte maturation pathways. Studies have suggested that exposure to BPA may cause an increase in meiotic disturbances in mice, such as aneuploidy in oocytes [32,33]. It is well documented that exposure to BPA in the prenatal period is associated with cystic endometrial hyperplasia, ovarian cysts, aneuploidy in oocytes, and a reduction in the primordial pool of follicles in mouse ovaries, indicating an association between BPA and the increased proliferation of ovarian cells mediated by estrogenic pathway [33][34][35].…”

Latest research and treatment of advanced-stage epithelial ovarian cancer

“…A recent Cochrane Review of the subject concluded that no treatment effect on PFS or overall survival could be demonstrated among the limited sample of phase III trials, which randomized patients with complete clinical response (cCR) to treatment versus placebo or observation. 51 Importantly, this review did not include the two bevacizumab trials discussed above 45, 46 , as these trials allowed patients with clinical partial response to proceed onto the randomized maintenance strategy. Subsequent to the Cochrane Review, another phase III trial of erlotinib (versus observation) was reported.…”

Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers

“…[ 74–78 ] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [ 61,79–81 ]…”

“…[74][75][76][77][78] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [61,[79][80][81] The course of the illness determines the feasibility of secondary cytoreduction surgery in these advanced cases, as well as the surgical strategy of choice, including open, laparoscopic, or robotic approaches. Pathological variables such as extrapelvic involvement, carcinomatosis, and extent of disease progression determine complete cytoreduction.…”

Impact of Environmentally Relevant Concentrations of Bisphenol A (BPA) on the Gene Expression Profile in an In Vitro Model of the Normal Human Ovary

“…The results show that BPA exposure has a considerable impact on 10 genes: ANAPC2, AURKA, CDK1, CCNA2, CCNB1, PLK1, BUB1, KIF22, PDE3B, and CCNB3, which are also associated with progesterone-mediated oocyte maturation pathways. Studies have suggested that exposure to BPA may cause an increase in meiotic disturbances in mice, such as aneuploidy in oocytes [32,33]. It is well documented that exposure to BPA in the prenatal period is associated with cystic endometrial hyperplasia, ovarian cysts, aneuploidy in oocytes, and a reduction in the primordial pool of follicles in mouse ovaries, indicating an association between BPA and the increased proliferation of ovarian cells mediated by estrogenic pathway [33][34][35].…”

Latest research and treatment of advanced-stage epithelial ovarian cancer

“…A recent Cochrane Review of the subject concluded that no treatment effect on PFS or overall survival could be demonstrated among the limited sample of phase III trials, which randomized patients with complete clinical response (cCR) to treatment versus placebo or observation. 51 Importantly, this review did not include the two bevacizumab trials discussed above 45, 46 , as these trials allowed patients with clinical partial response to proceed onto the randomized maintenance strategy. Subsequent to the Cochrane Review, another phase III trial of erlotinib (versus observation) was reported.…”

Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers

“…[ 74–78 ] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [ 61,79–81 ]…”

“…[74][75][76][77][78] While novel PARP inhibitors have demonstrated improvements in overall survival (OS) for patients with epithelial ovarian cancer (EOC), conventional maintenance chemotherapy given after initial treatment does not lead to significant enhancements in survival outcomes. [61,[79][80][81] The course of the illness determines the feasibility of secondary cytoreduction surgery in these advanced cases, as well as the surgical strategy of choice, including open, laparoscopic, or robotic approaches. Pathological variables such as extrapelvic involvement, carcinomatosis, and extent of disease progression determine complete cytoreduction.…”

Impact of Environmentally Relevant Concentrations of Bisphenol A (BPA) on the Gene Expression Profile in an In Vitro Model of the Normal Human Ovary

“…The results show that BPA exposure has a considerable impact on 10 genes: ANAPC2, AURKA, CDK1, CCNA2, CCNB1, PLK1, BUB1, KIF22, PDE3B, and CCNB3, which are also associated with progesterone-mediated oocyte maturation pathways. Studies have suggested that exposure to BPA may cause an increase in meiotic disturbances in mice, such as aneuploidy in oocytes [32,33]. It is well documented that exposure to BPA in the prenatal period is associated with cystic endometrial hyperplasia, ovarian cysts, aneuploidy in oocytes, and a reduction in the primordial pool of follicles in mouse ovaries, indicating an association between BPA and the increased proliferation of ovarian cells mediated by estrogenic pathway [33][34][35].…”

Latest research and treatment of advanced-stage epithelial ovarian cancer

“…A recent Cochrane Review of the subject concluded that no treatment effect on PFS or overall survival could be demonstrated among the limited sample of phase III trials, which randomized patients with complete clinical response (cCR) to treatment versus placebo or observation. 51 Importantly, this review did not include the two bevacizumab trials discussed above 45, 46 , as these trials allowed patients with clinical partial response to proceed onto the randomized maintenance strategy. Subsequent to the Cochrane Review, another phase III trial of erlotinib (versus observation) was reported.…”